FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer

Authors:

Abstract
Genomic alterations in fibroblast growth factor receptor (FGFR) genes are present in a small number of metastatic pancreatic ductal adenocarcinomas (PDAC) and may represent an emerging subgroup of patients likely to benefit from FGFR targeted therapies. Here we present four FGFR2 fusion-positive metastatic PDAC patients who exhibited durable responses or disease control to FGFR kinase inhibitors. Utilizing our custom FGFR focused cell-free DNA assay, FGFR-Dx, we serially monitored variant allele fractions of FGFR2 fusions during FGFR inhibitor treatment and observed dynamic changes correlating with clinical responses. Genomic analysis of 30,229 comprehensively profiled pancreatic cancers revealed FGFR1-3 fusions in 245 cases, an incidence of 0.81%. FGFR fusions were generally mutually exclusive from other known oncogenes. Our findings provide clinical evidence for identifying and treating FGFR2 fusion-positive PDAC patients with FGFR targeted therapy.
Funding Information
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (UH3 CA262220)
  • Gateway for Cancer Research (AWD-110943, AWD-114129)
  • U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (T32 TR004543)

This publication has 33 references indexed in Scilit: